IVIg Controls Dermatomyositis in Phase 3 Trial IVIg Controls Dermatomyositis in Phase 3 Trial

Intravenous immunoglobulin was safe and effective for dermatomyositis in the first multinational, phase 3, placebo-controlled trial to evaluate the treatment.Medscape Medical News

Source: Medscape Dermatology Headlines - June 3, 2021 Category: Dermatology Tags: Rheumatology News Source Type: news